DEA Faces Backlash Over Psychedelics Ban Proposal From Student Advocacy Group

A national drug policy reform organization is challenging the DEA’s proposal to ban two psychedelic substances, arguing the move would hinder critical scientific research. As reported by Marijuana Moment, the nonprofit Students for Sensible Drug Policy (SSDP) presented their case in a prehearing statement to the DEA’s administrative court on Tuesday.

The DEA plans to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA). This classification is reserved for substances with high abuse potential and no accepted medical use. However, the SSDP, representing 20 graduate students, researchers and professors, are contesting the move, arguing for the therapeutic potential of these compounds.

The petitioners argue the agency has not provided sufficient evidence to support the high abuse potential claim. According to SSDP, there are no documented cases of harmful effects or dependence related to DOI and DOC in medical literature. “DOI and DOC are important research chemicals with basically no evidence of abuse,” stated Brett Phelps, SSDP alum and its legal counsel.

Impact on Research

Experts warn that scheduling these psychedelics would severely impact ongoing research. “DEA’s proposed rulemaking defies scientific study and will make it more difficult for researchers to work on the serotonin 2 receptor,” said Elijah Ullman, chair of SSDP’s Science Policy Committee. The serotonin 2 receptor plays a crucial role in regulating learning, memory and mood.

Historical Context

This challenge is part of a longer battle between the DEA and the scientific community. In 2022, the agency first attempted to list these substances, but the proposal was withdrawn after significant pushback. The DEA renewed its efforts last December, continuing the contentious debate.

Research over the past 35 years, including studies funded by federal health agencies, suggests DOI and DOC may be effective in treating chronic pain, opioid and alcohol addiction and other mental health disorders. Kat Murti, SSDP executive director underscored the broader implications. “This is about preserving the integrity of scientific inquiry, advancing medical treatment, and ultimately, impacting lives positively.”

Future Implications

As the DEA moves forward with its proposal, the scientific community and advocacy groups remain vigilant. The debate underscores the need for balanced drug policy that considers both potential abuse and therapeutic benefits.

Cover image made with AI